BioNTech Puts $200M Into Collab With Cancer Biotech Autolus
German immunotherapy company BioNTech will inject $200 million into cancer-focused biotechnology firm Autolus Therapeutics PLC as part of a strategic collaboration announced Thursday....To view the full article, register now.
Already a subscriber? Click here to view full article